Dova Pharmaceuticals, Inc. (DOVA) Given $34.00 Consensus Target Price by Analysts
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation. Dova Pharmaceuticals’ rating score has improved by 40.1% in the last three months as a result of various analysts’ ratings changes.
Brokers have set a one year consensus target price of $34.00 for the company, according to Zacks. Zacks has also given Dova Pharmaceuticals an industry rank of 104 out of 265 based on the ratings given to related companies.
Several research firms have recently weighed in on DOVA. Jefferies Group lifted their target price on shares of Dova Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, November 28th. Zacks Investment Research upgraded shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a research note on Wednesday, October 11th. Finally, Leerink Swann upgraded shares of Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 target price for the company in a research note on Tuesday, September 26th.
Shares of Dova Pharmaceuticals (DOVA) traded down $0.17 during mid-day trading on Friday, reaching $29.92. 24,400 shares of the company’s stock traded hands, compared to its average volume of 114,990. Dova Pharmaceuticals has a twelve month low of $16.98 and a twelve month high of $30.48.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.08). During the same period in the previous year, the firm posted ($0.41) EPS. equities analysts forecast that Dova Pharmaceuticals will post -1.51 EPS for the current year.
Large investors have recently modified their holdings of the stock. California State Teachers Retirement System purchased a new position in Dova Pharmaceuticals during the third quarter valued at approximately $202,000. Laurion Capital Management LP purchased a new position in Dova Pharmaceuticals during the second quarter valued at approximately $223,000. Schwab Charles Investment Management Inc. purchased a new position in Dova Pharmaceuticals during the third quarter valued at approximately $241,000. Bank of New York Mellon Corp purchased a new position in Dova Pharmaceuticals during the third quarter valued at approximately $340,000. Finally, JPMorgan Chase & Co. purchased a new position in Dova Pharmaceuticals during the second quarter valued at approximately $382,000. 26.20% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Dova Pharmaceuticals, Inc. (DOVA) Given $34.00 Consensus Target Price by Analysts” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://theolympiareport.com/2017/12/05/dova-pharmaceuticals-inc-dova-given-34-00-consensus-target-price-by-analysts.html.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.